リブラメディシーナ Company Overview

We will be exhibiting at BioJapan 2026 On the day of the event, we will be working alongside our partner companies to address your needs. We sincerely look forward to seeing you there. [Booth No. C-66] 　　・LibraMedicina 　　・Synmax Biochemical (Intermediate manufacturing, fermentation technology, biotransformation) [Booth No. C-71 (adjacent)] ・Mycenax Biotech (CDMO, our business partner) Translated with DeepL.com (free version)

[Notice of Appointment of Director] We are pleased to announce that Makoto Kawaguchi has been appointed as a director of our company, effective April 1, 2026 (Reiwa 8), in order to strengthen our management structure. We will continue to make every effort for the development of the pharmaceutical and medical fields, and we appreciate your continued support and kindness. Thank you very much.

Our partner company, Mycenax, conducted an on-site inspection by the EMA (in January 2025) and received formal periodic synthesis approval notification in March 2025. As a result, we have completed inspections by regulatory authorities in Japan, Canada, and Europe over the last two quarters and received official "pass" notifications. 【Health Canada】 (October 2024) – Conducted a 5-day on-site inspection, completed one day ahead of schedule. Received formal "pass" notification in December 2024. 【PMDA】 (November 2024) – Conducted a 4-day on-site inspection, completed half a day ahead of schedule. Received formal "pass" notification in February 2025. 【EMA】 (January 2025) – Conducted a 10-day on-site inspection, completed two days ahead of schedule. Received formal "pass" notification in March 2025. The fact that these inspections were completed earlier than initially planned indicates that Mycenax's manufacturing facilities and quality management systems are highly regarded by international regulatory authorities.